跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Sangstat
首页
药物
Sangstat
Sangstat
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Method for producing human anti-thymocyte immunoglobulins
申请人: SANGSTAT MEDICAL CORP
优先权: 2000
US
2 件公开
Cytomodulating conjugates of members of specific binding pairs
申请人: SANGSTAT MEDICAL CORP
优先权: 2005
US
Cytomodulating peptides for treating interstitial cystitis
申请人: SANGSTAT MEDICAL CORP
优先权: 2002
US
2 件公开
Methods for enhancing graft survival by modulating heme oxygenase activity
申请人: SANGSTAT MEDICAL CORP
优先权: 2000
US
2 件公开
Cytomodulating peptide for inhibiting lymphocyte activity
申请人: SANGSTAT MEDICAL CORP
优先权: 2000
US
Pharmaceutical compositions for bioactive peptide agents
申请人: SANGSTAT MEDICAL CORP
优先权: 2004
US
Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
申请人: SANGSTAT MEDICAL CORP
优先权: 2001
CN
Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes
申请人: INST NAT SANTE RECH MED
优先权: 1999
US
3 件公开
药物
反馈